廣告

Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms

Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms

Regeneron stock jumped early Thursday, bolstered by strong sales of a high-dose version of its blockbuster eye disease treatment, Eylea.